NANOBIOTIX Presents NBTXR3 Preclinical Data Demonstrating Its Potential Usage as in Situ Vaccine for Cancer
at the Society for Immunotherapy of Cancer Annual Meeting
Regulatory News:
NANOBIOTIX (Paris:NANO)(Euronext: NANO – ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering novel
approaches for the local treatment of cancer, today announces preclinical data demonstrating that its leading radioenhancer
nanoparticle, NBTXR3, actively stimulates the host immune system to attack tumor cells. These data from the ongoing NBTXR3
immuno-oncology preclinical program were presented at one of the leading global immuno-oncology conferences, the 31st Annual Meeting of the Society for Immunotherapy of Cancer (SITC), being held November 9-13, 2016 in
National Harbor, Maryland, USA (Paris S., Pottier A., Levy L., and Lu B. Hafnium oxide nanoparticles, a radiation enhancer for in
situ cancer vaccine).
Laurent Levy, CEO of Nanobiotix, commented: “These exciting data show that NBTXR3 could be a potential game changer in
Immuno-oncology combination landscape. This raises the possibility of synergies between NBTXR3, radiotherapy and immunotherapies.
On the top of existing core developments of our product as a single agent, this is opening new doors for industrial
collaborations.”
Data presented showing the potential of NBTXR3 in Immuno-Oncology
During the presentation, Nanobiotix scientists and Dr. Bo Lu, MD, Director of the Molecular Radiation Biology in the Department
of Radiation Oncology at the Thomas Jefferson University Hospital in Philadelphia, presented study results which demonstrate that
radiotherapy with NBTXR3 elicits a marked enhancement of Immunogenic Cell Death (ICD) compared to radiotherapy alone across
different cancer cell lines, in radioresistant or radiosensitive models.
In a second experiment, the phenomenon known as the abscopal effect was evaluated (i.e. an effect outside the scope of the
localized treatment). Two tumors were implanted on both sides of mice, and subsequently only one tumor was treated with
NBTXR3-radiation therapy. As a result, both tumors demonstrated volume shrinkage. Specifically, the study showed that use of NBTXR3
in combination with radiotherapy resulted in a control on the untreated tumor and a statistically significant increase of overall
survival. No abscopal effect was observed in control groups and group treated with radiation therapy alone.
A third experiment has demonstrated that NBTXR3 combined with radiotherapy could be used to create a vaccine ex vivo with
a higher rate of long term vaccination success when compared to radiotherapy alone.
Elsa Borghi, CMO of Nanobiotix commented: “Although immunotherapies hold great promise in treating cancer, one of the main
barriers is that most of tumors do not provoke an immune response, which renders immunotherapy ineffective in many patients. The
findings from this research indicate that NBTXR3 could have the potential to transform a tumor into an in situ vaccine. It could
convert an immunologically ‘cold’ tumor, which does not provoke an immune response, to a ‘hot’ tumor, which induces an immune
response and therefore provokes a host immune response to attack tumor cells.”
NBTXR3 competitive positioning in Immuno-Oncology
Radiotherapy is an established standard of care in many solid tumor types (approximately 60% of all cancer patients receive
radiotherapy). Compared to other products used for priming of the tumor, currently in development for Immuno-Oncology, NBTXR3 could
have a number of advantages: a physical and universal mode of action that could be used widely across oncology, one time local
injection, a good fit within existing medical practice already used a base for cancer treatment, limited or no systemic toxicity,
and a well-established manufacturing process.
Radiotherapy is often given within the first lines of cancer treatment, compare to most current positioning of immuno-oncology
development in a later stage treatment. A successful approach using NBTXR3 in immuno-oncology could make it a key player by
offering treatment options in earlier stages of the disease.
Taken together, these data indicate that radiotherapy in combination with NBTXR3 could play a key role in immuno- oncology and
could be used in synergy with several immuno-oncology approaches to increase patient responses across many different types of
cancer.
NBTXR3 current clinical development as a single agent
Outside immuno-oncology field and as a single agent, NBTXR3 is in late stage clinical development, for its capability to enhance
the dose of radiotherapy within the tumor and more efficiently destroy cancer cells. Worldwide clinical development is currently
covering seven patient populations and a first market approval has been filed in EU in August 2016.
●●●
About NBTXR3
Nanobiotix’s lead product, NBTXR3, is a first-in-class radio-enhancer nanoparticle designed for direct injection into cancerous
tumors. It has been engineered to increase the dose and efficacy of radiotherapy without increasing toxicity or causing damage to
surrounding healthy tissues. NBTXR3 is currently in late-stage clinical development as a single agent.
Worldwide clinical development of NBTXR3 now includes trials across 7 patient populations:
- Soft Tissue Sarcoma (STS)
Phase I/II trial completed
Phase II/III “Act.in.Sarc.” global trial (including EU, South Africa and Asia-Pacific region)
- Head and Neck Cancer
Phase I/II trial in France and Spain; NBTXR3 + Radiotherapy alone
Phase I/II trial by PharmaEngine in Asia-Pacific; NBTXR3 + Radiotherapy & Chemotherapy
- Prostate Cancer
Phase I/II trial in the U.S
- Liver Cancers
Phase I/II Hepatocellular Cancer trial in France
Phase I/II Liver Metastases trial in France
- Rectal Cancer
Phase I/II trial by PharmaEngine in Asia-Pacific
First market approval has been filed in the EU and could be obtained in 2017.
About NANOBIOTIX: www.nanobiotix.com
Nanobiotix (Euronext: NANO / ISIN: FR0011341205) is a late clinical-stage nanomedicine company pioneering novel approaches for
the local treatment of cancer. The Company’s first-in-class, proprietary technology, NanoXray, enhances radiotherapy energy with a
view to provide a new, more efficient treatment for cancer patients.
NanoXray products are compatible with current radiotherapy treatments and are meant to treat potentially a wide variety of solid
tumors including soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, breast cancer, glioblastoma, etc., via
multiple routes of administration.
Nanobiotix’s lead product NBTXR3, based on NanoXray, is currently under clinical development for soft tissue sarcoma, head and
neck cancer, prostate cancer, and liver cancers (HCC and liver metastases) as well as head and neck and rectal cancers under trial
by PharmaEngine. The Company has filed in August 2016 for market approval (CE Marking) in Europe for its lead product NBTXR3. The
Company has partnered with PharmaEngine for clinical development and commercialization of NBTXR3 in Asia.
Nanobiotix is listed on the regulated market of Euronext in Paris (ISIN: FR0011341205, Euronext ticker: NANO, Bloomberg: NANO:
FP). The Company Headquarter is based in Paris, France. Affiliate in Cambridge, United States.
For more information, please visit www.nanobiotix.com
Disclaimer
This press release contains certain forward-looking statements concerning Nanobiotix and its business. Such forward-looking
statements are based on assumptions that Nanobiotix considers to be reasonable. However, there can be no assurance that the
estimates contained in such forward-looking statements will be verified, which estimates are subject to numerous risks including
the risks set forth in the reference document of Nanobiotix filed with the French Financial Markets Authority (Autorité des Marchés
Financiers) under number D.16-0732 on July 22, 2016 (a copy of which is available on www.nanobiotix.com) and to the development of economic conditions, financial markets and the markets in which
Nanobiotix operates. The forward-looking statements contained in this press release are also subject to risks not yet known to
Nanobiotix or not currently considered material by Nanobiotix. The occurrence of all or part of such risks could cause actual
results, financial conditions, performance or achievements of Nanobiotix to be materially different from such forward-looking
statements.
This press release and the information that it contains do not constitute an offer to sell or subscribe for, or a
solicitation of an offer to purchase or subscribe for, Nanobiotix shares in any country.
Nanobiotix
Sarah Gaubert, +33 (0)1 40 26 07 55
Head of Communication and Public Affairs
contact@nanobiotix.com
or
Media relations
France - Springbok Consultants
Marina Rosoff, +33 (0)6 71 58 00 34
marina@springbok.fr
or
EU Outside France - Instinctif Partners
Melanie Toyne Sewell, +44 (0) 207 457 2020
nanobiotix@instinctif.com
or
United States – The Ruth Group
Kirsten Thomas / Chris Hippolyte
+1 508-280-6592 / +1 646-536-7023
Nanobiotix@theruthgroup.com
View source version on businesswire.com: http://www.businesswire.com/news/home/20161113005096/en/